Interferon γ-Induced Protein10 Kinetics in Treatment-Naive Versus Treatment-Experienced Patients Receiving Interferon-Free Therapy for Hepatitis C Virus Infection: Implications for the Innate Immune Response

被引:20
|
作者
Lin, Jennifer C. [1 ]
Habersetzer, Francois [7 ,8 ,9 ]
Rodriguez-Torres, Maribel [6 ]
Afdhal, Nezam [3 ]
Lawitz, Eric J. [4 ]
Paulson, Matthew S. [2 ]
Zhu, Yanni [2 ]
Subramanian, Gangadharan Mani [2 ]
McHutchison, John G. [2 ]
Sulkowski, Mark [5 ]
Wyles, David L. [1 ]
Schooley, Robert T. [1 ]
机构
[1] Univ Calif San Diego, La Jolla, CA 92093 USA
[2] Gilead Sci, Foster City, CA USA
[3] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
[4] Alamo Med Res, San Antonio, TX USA
[5] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
[6] Fdn Invest Diego, San Juan, PR USA
[7] Hop Univ Strasbourg, Strasbourg, France
[8] INSERM 1110, Strasbourg, France
[9] Univ Strasbourg, Strasbourg, France
来源
JOURNAL OF INFECTIOUS DISEASES | 2014年 / 210卷 / 12期
基金
美国国家卫生研究院;
关键词
IP-10; hepatitis C; direct-acting antiviral therapy; innate immunity; INDUCIBLE PROTEIN-10; INFLAMMATION; RIBAVIRIN; CORRELATE; FIBROSIS; PREDICTS;
D O I
10.1093/infdis/jiu325
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
We measured interferon gamma-induced protein 10 (IP-10) levels in 428 patients at baseline, week 1, and week 2 of all-oral treatment for hepatitis C virus (HCV) infection. An increased baseline IP-10 level was associated with a T allele in the IL28B gene, an increased alanine aminotransferase level in treatment-naive but not experienced patients, and an increased body mass index. At week 1, the mean decline in plasma IP-10 levels was the same in treatment-naive and treatment-experienced patients (-49%), whereas during week 2 the mean decline in IP-10 levels in treatment-naive patients (-14%) was significantly larger than in treatment-experienced patients (-2%; P =.0176). IP-10 thus may be a surrogate marker of the rate of intracellular viral replication complex decay.
引用
收藏
页码:1881 / 1885
页数:5
相关论文
共 50 条
  • [1] Optimal interferon-free therapy in treatment-experienced chronic hepatitis C patients
    Peter, Joy
    Nelson, David R.
    LIVER INTERNATIONAL, 2015, 35 : 65 - 70
  • [2] SOFOSBUVIR PLUS RIBAVIRIN, AN INTERFERON-FREE REGIMEN, IN THE TREATMENT OF TREATMENT-NAIVE AND TREATMENT-EXPERIENCED PATIENTS WITH CHRONIC GENOTYPE 4 HCV INFECTION
    Ruane, P. J.
    Ain, D.
    Meshrekey, R.
    Riad, J.
    Soliman, M.
    Mikhail, S.
    Wolfe, P. R.
    Kersey, K.
    Doehle, B.
    Jiang, D.
    Symonds, W. T.
    JOURNAL OF HEPATOLOGY, 2014, 60 (01) : S503 - S504
  • [3] Role of ribavirin in interferon-free therapy for the treatment of hepatitis C virus
    Maria Morillas, Rosa
    Masnou, Helena
    Ardevol, Merce
    Lopez, Dulce
    GASTROENTEROLOGIA Y HEPATOLOGIA, 2017, 40 (10): : 699 - 708
  • [4] Modelling how responsiveness to interferon improves interferon-free treatment of hepatitis C virus infection
    Venugopal, Vishnu
    Padmanabhan, Pranesh
    Raja, Rubesh
    Dixit, Narendra M.
    PLOS COMPUTATIONAL BIOLOGY, 2018, 14 (07)
  • [5] Immunogenicity of recombinant hepatitis B vaccine in treatment-naive and treatment-experienced chronic hepatitis C patients: The effect of pegylated interferon plus ribavirin treatment
    Elefsiniotis, Ioannis S.
    Vezali, Elena
    Kamposioras, Konstantinos
    D Pantazis, Konstantinos
    Tontorova, Raclostina
    Ketikoglou, Ioannis
    Moulakakis, Antonios
    Saroglou, George
    WORLD JOURNAL OF GASTROENTEROLOGY, 2006, 12 (27) : 4420 - 4424
  • [6] The changing landscape of hepatitis C virus therapy: focus on interferon-free treatment
    Lam, Brian P.
    Jeffers, Thomas
    Younoszai, Zahra
    Fazel, Yousef
    Younossi, Zobair M.
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2015, 8 (05): : 298 - 312
  • [7] Interferon-free treatment of chronic hepatitis C virus infection in patients with inherited bleeding disorders
    Wiegand, Johannes
    Schiefke, Ingolf
    Stein, Kerstin
    Berg, Thomas
    Kullig, Ulrike
    Ende, Katrin
    HAMOSTASEOLOGIE, 2017, 37 (02): : 127 - 130
  • [8] SOFOSBUVIR PLUS SIMEPREVIR IN TREATMENT-NAIVE AND TREATMENT-EXPERIENCED EGYPTIAN PATIENTS WITH HEPATITIS C VIRUS INFECTION: A REAL LIFE EXPERIENCE
    Esmat, G.
    Eldeen, H. G.
    El Kassas, M.
    El Raziky, M.
    Elbaz, T.
    Fouad, R.
    Hussein, M.
    El-Hossary, W.
    Cordie, A.
    Korany, M.
    Abdelfattah, A.
    Doss, W.
    Yosry, A.
    JOURNAL OF HEPATOLOGY, 2016, 64 : S769 - S770
  • [9] Hepatitis C virus genotype 4-infection and interferon-free treatment in Egypt
    Tatsuo Kanda
    Shunichi Matsuoka
    Mitsuhiko Moriyama
    Hepatology International, 2018, 12 : 291 - 293
  • [10] Hepatitis C virus genotype 4-infection and interferon-free treatment in Egypt
    Kanda, Tatsuo
    Matsuoka, Shunichi
    Moriyama, Mitsuhiko
    HEPATOLOGY INTERNATIONAL, 2018, 12 (04) : 291 - 293